LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Wheaton Acquires Bioreactor Flask Line from Wilson Wolf

By LabMedica International staff writers
Posted on 25 Jul 2012
Wheaton Industries (Millville, NJ, USA) has acquired the CELLine bioreactor flask line for antibody and protein production from Wilson Wolf Manufacturing Corp. (New Brighton, MN, USA).

Wheaton has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corp. Wheaton has also entered into a long term strategic partnership with Wilson Wolf Manufacturing for additional product development in high density cell culture devices for the production of concentrated, cell secreted products.

CELLine flasks are easy to implement and are known worldwide for small-scale suspension and adherent cultures. The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.

The flasks enhance small-scale bioproduction for antibody and protein generation. Conventional in vivo or in vitro cell culture methods can be labor-intensive, result in low cell density, and require significant purification. The CELLine flasks address these three areas of limitation in a single use, repeatable technology. CELLine flasks are ready-to-use and disposable, and generate high cell density and high product concentration, while considerably reducing culture and processing time.

“We are excited to bring this innovative, high growth technology to Wheaton and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing Wheaton portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, president of Wheaton. “We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.

Related Links:

Wheaton Industries
Wilson Wolf Manufacturing


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
PURITAN MEDICAL